Reported Standalone quarterly numbers for Glenmark Pharma are:
Net Sales at Rs 1,538.66 crore in September 2025 down 41.63% from Rs. 2,636.10 crore in September 2024.
Story continues below Advertisement
Quarterly Net Loss at Rs. 739.19 crore in September 2025 down 224.22% from Rs. 595.06 crore in September 2024.
EBITDA stands at Rs. 107.75 crore in September 2025 down 87.5% from Rs. 861.70 crore in September 2024.
Glenmark shares closed at 1,844.20 on November 20, 2025 (NSE) and has given 28.06% returns over the last 6 months and 25.76% over the last 12 months.
Story continues below Advertisement
| Glenmark Pharma | | Standalone Quarterly Results | in Rs. Cr. |
|
| Sep'25 | Jun'25 | Sep'24 | | Net Sales/Income from operations | 1,219.53 | 2,178.90 | 2,594.89 | | Other Operating Income | 319.13 | 216.03 | 41.21 | | Total Income From Operations | 1,538.66 | 2,394.93 | 2,636.10 | | EXPENDITURE | | Consumption of Raw Materials | 667.82 | 677.24 | 722.57 | | Purchase of Traded Goods | 91.31 | 99.33 | 103.65 | | Increase/Decrease in Stocks | -102.85 | -58.41 | 7.88 | | Power & Fuel | -- | -- | -- | | Employees Cost | 453.68 | 408.44 | 408.42 | | Depreciation | 58.93 | 57.64 | 54.85 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 606.70 | 540.17 | 614.96 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | -236.93 | 670.52 | 723.78 | | Other Income | 285.76 | 69.34 | 83.08 | | P/L Before Int., Excpt. Items & Tax | 48.82 | 739.86 | 806.85 | | Interest | 23.40 | 15.46 | 11.80 | | P/L Before Exceptional Items & Tax | 25.43 | 724.40 | 795.06 | | Exceptional Items | -931.79 | -323.23 | -- | | P/L Before Tax | -906.37 | 401.17 | 795.06 | | Tax | -167.18 | 70.94 | 200.00 | | P/L After Tax from Ordinary Activities | -739.19 | 330.23 | 595.06 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -739.19 | 330.23 | 595.06 | | Equity Share Capital | 28.22 | 28.22 | 28.22 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -26.19 | 11.70 | 21.09 | | Diluted EPS | -26.19 | 11.70 | 21.09 | | EPS After Extra Ordinary | | Basic EPS | -26.19 | 11.70 | 21.09 | | Diluted EPS | -26.19 | 11.70 | 21.09 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
